vs
Side-by-side financial comparison of BGSF, INC. (BGSF) and Entrada Therapeutics, Inc. (TRDA). Click either name above to swap in a different company.
BGSF, INC. is the larger business by last-quarter revenue ($22.0M vs $20.6M, roughly 1.1× Entrada Therapeutics, Inc.). BGSF, INC. runs the higher net margin — -5.3% vs -84.4%, a 79.1% gap on every dollar of revenue. On growth, BGSF, INC. posted the faster year-over-year revenue change (-9.4% vs -65.2%). BGSF, INC. produced more free cash flow last quarter ($1.7M vs $-39.7M). Over the past eight quarters, Entrada Therapeutics, Inc.'s revenue compounded faster (6.4% CAGR vs -5.3%).
BGSF Inc. is a leading U.S.-headquartered workforce solutions firm that provides tailored staffing, talent recruitment, and end-to-end workforce management services. It serves core segments including information technology, healthcare, professional administration, light industrial, and creative industries, catering to small, mid-sized and large enterprise clients across North America.
Entrada Therapeutics is a clinical-stage biotechnology firm developing transformative intracellular therapies for serious rare diseases and high-unmet-need disorders. Its pipeline covers neuromuscular, metabolic, and central nervous system segments, serving global patients via healthcare partnerships.
BGSF vs TRDA — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2025
| Metric | | |
|---|---|---|
| Revenue | $22.0M | $20.6M |
| Net Profit | $-1.2M | $-17.3M |
| Gross Margin | 35.0% | — |
| Operating Margin | -17.6% | -106.0% |
| Net Margin | -5.3% | -84.4% |
| Revenue YoY | -9.4% | -65.2% |
| Net Profit YoY | -18.2% | -173.8% |
| EPS (diluted) | $-0.12 | $-0.42 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $22.0M | — | ||
| Q3 25 | $26.9M | — | ||
| Q2 25 | $23.5M | — | ||
| Q1 25 | $20.9M | $20.6M | ||
| Q4 24 | $24.3M | $37.4M | ||
| Q3 24 | $29.8M | $19.6M | ||
| Q2 24 | $25.7M | $94.7M | ||
| Q1 24 | $24.5M | $59.1M |
| Q4 25 | $-1.2M | — | ||
| Q3 25 | $-5.8M | — | ||
| Q2 25 | $-3.7M | — | ||
| Q1 25 | $-722.0K | $-17.3M | ||
| Q4 24 | $-981.0K | $1.1M | ||
| Q3 24 | $-804.0K | $-14.0M | ||
| Q2 24 | $-761.0K | $55.0M | ||
| Q1 24 | $-792.0K | $23.5M |
| Q4 25 | 35.0% | — | ||
| Q3 25 | 35.9% | — | ||
| Q2 25 | 35.8% | — | ||
| Q1 25 | 36.2% | — | ||
| Q4 24 | 35.9% | — | ||
| Q3 24 | 35.9% | — | ||
| Q2 24 | 37.3% | — | ||
| Q1 24 | 38.1% | — |
| Q4 25 | -17.6% | — | ||
| Q3 25 | -3.5% | — | ||
| Q2 25 | -18.8% | — | ||
| Q1 25 | 1.6% | -106.0% | ||
| Q4 24 | -15.7% | -15.7% | ||
| Q3 24 | -3.4% | -110.7% | ||
| Q2 24 | -5.7% | 56.4% | ||
| Q1 24 | 1.7% | 35.7% |
| Q4 25 | -5.3% | — | ||
| Q3 25 | -21.6% | — | ||
| Q2 25 | -15.9% | — | ||
| Q1 25 | -3.5% | -84.4% | ||
| Q4 24 | -4.0% | 3.0% | ||
| Q3 24 | -2.7% | -71.7% | ||
| Q2 24 | -3.0% | 58.1% | ||
| Q1 24 | -3.2% | 39.7% |
| Q4 25 | $-0.12 | — | ||
| Q3 25 | $-0.52 | — | ||
| Q2 25 | $-0.34 | — | ||
| Q1 25 | $-0.06 | $-0.42 | ||
| Q4 24 | — | $-0.20 | ||
| Q3 24 | $-0.07 | $-0.35 | ||
| Q2 24 | $-0.07 | $1.55 | ||
| Q1 24 | — | $0.68 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $67.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $48.1M | $417.3M |
| Total Assets | $57.8M | $486.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | — | ||
| Q3 25 | $41.2M | — | ||
| Q2 25 | $2.8M | — | ||
| Q1 25 | $2.0M | $67.8M | ||
| Q4 24 | $32.0K | $101.2M | ||
| Q3 24 | $262 | $78.0M | ||
| Q2 24 | $226 | $185.3M | ||
| Q1 24 | $50 | $68.4M |
| Q4 25 | $48.1M | — | ||
| Q3 25 | $50.7M | — | ||
| Q2 25 | $78.3M | — | ||
| Q1 25 | $81.8M | $417.3M | ||
| Q4 24 | $82.3M | $428.7M | ||
| Q3 24 | $82.9M | $422.4M | ||
| Q2 24 | $83.2M | $429.9M | ||
| Q1 24 | $83.6M | $269.4M |
| Q4 25 | $57.8M | — | ||
| Q3 25 | $83.6M | — | ||
| Q2 25 | $149.7M | — | ||
| Q1 25 | $152.3M | $486.5M | ||
| Q4 24 | $150.1M | $526.3M | ||
| Q3 24 | $157.3K | $554.6M | ||
| Q2 24 | $159.8K | $582.0M | ||
| Q1 24 | $170.6K | $510.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $1.7M | $-38.5M |
| Free Cash FlowOCF − Capex | $1.7M | $-39.7M |
| FCF MarginFCF / Revenue | 7.6% | -192.9% |
| Capex IntensityCapex / Revenue | 0.1% | 5.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-16.0K | $-58.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.7M | — | ||
| Q3 25 | $-4.8M | — | ||
| Q2 25 | $2.2M | — | ||
| Q1 25 | $1.1M | $-38.5M | ||
| Q4 24 | $3.2M | $-31.6M | ||
| Q3 24 | $6.5M | $-24.3M | ||
| Q2 24 | $7.3M | $39.8M | ||
| Q1 24 | $7.4M | $-25.5M |
| Q4 25 | $1.7M | — | ||
| Q3 25 | $-4.9M | — | ||
| Q2 25 | $2.1M | — | ||
| Q1 25 | $1.0M | $-39.7M | ||
| Q4 24 | $2.5M | $-32.2M | ||
| Q3 24 | $6.5M | $-24.9M | ||
| Q2 24 | $7.3M | $38.8M | ||
| Q1 24 | $6.9M | $-26.4M |
| Q4 25 | 7.6% | — | ||
| Q3 25 | -18.1% | — | ||
| Q2 25 | 9.1% | — | ||
| Q1 25 | 5.0% | -192.9% | ||
| Q4 24 | 10.2% | -86.2% | ||
| Q3 24 | 21.7% | -127.3% | ||
| Q2 24 | 28.5% | 41.0% | ||
| Q1 24 | 28.1% | -44.6% |
| Q4 25 | 0.1% | — | ||
| Q3 25 | 0.4% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.1% | 5.6% | ||
| Q4 24 | 3.0% | 1.7% | ||
| Q3 24 | 0.0% | 3.3% | ||
| Q2 24 | 0.0% | 1.1% | ||
| Q1 24 | 2.0% | 1.4% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -27.94× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.72× | ||
| Q1 24 | — | -1.09× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BGSF
| Contract Field Talent | $21.4M | 97% |
| Other | $595.0K | 3% |
TRDA
Segment breakdown not available.
